Indication

Metastatic malignant melanoma

Metastatic malignant melanoma is an advanced, highly aggressive form of cancer arising from transformed melanocytes, typically originating in the skin but occasionally in mucosal membranes or the uvea. Read more about Metastatic malignant melanoma

15 drugs 12 manufacturers

Advertisement

Drugs that treat it

Common Metastatic malignant melanoma therapies.

Showing 1–9 of 15 drugs

DACARBAZINE

METASTATIC MALIGNANT MELANOMA·+1
APP PHARMACEUTI

YERVOY (ipilimumab)

ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB·METASTATIC MALIGNANT MELANOMA·+8
BMS PRIMARYCARE

DACARBAZINE

METASTATIC MALIGNANT MELANOMA·+1
SICOR PHARM.

OPDIVO (nivolumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE

DACARBAZINE

METASTATIC MALIGNANT MELANOMA·+1
APP/FRESENIUS K
Filter & compare in the drug finder →Opens the drug finder with Metastatic malignant melanoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Metastatic malignant melanoma.

Metastatic malignant melanoma is an advanced, highly aggressive form of cancer arising from transformed melanocytes, typically originating in the skin but occasionally in mucosal membranes or the uvea.

It is pathophysiologically characterized by the hematogenous and lymphatic dissemination of malignant cells beyond regional lymph nodes into distant anatomical sites, most commonly the lungs, liver, brain, bones, distant subcutaneous tissues, and nonregional lymph nodes.

Patients with stage IV disease frequently present with systemic symptoms, organ-specific dysfunctions corresponding to metastatic foci, elevated serum lactate dehydrogenase levels, and oncogenic driver alterations such as BRAF mutations.

Personalize your experience

Follow Metastatic malignant melanoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it